Terms: = Bone cancer AND IRF4, LSIRF, 3662, ENSG00000137265, Q15306 AND Treatment
21 results:
1. Phenotype-structured model of intra-clonal heterogeneity and drug resistance in multiple myeloma.
Bouchnita A; Volpert V
J Theor Biol; 2024 Jan; 576():111652. PubMed ID: 37952610
[TBL] [Abstract] [Full Text] [Related]
2. Longitudinal treatment outcomes of recurrent clival chordomas: a single-center retrospective study.
Hong S; Mahajan A; Shinya Y; Laack NN; Link MJ; O'Brien EK; Stokken JK; Janus JR; Ho TP; Choby G; Van Gompel JJ
J Neurosurg; 2024 Apr; 140(4):920-928. PubMed ID: 37856417
[TBL] [Abstract] [Full Text] [Related]
3. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.
Mostofa A; Distler A; Meads MB; Sahakian E; Powers JJ; Achille A; Noyes D; Wright G; Fang B; Izumi V; Koomen J; Rampakrishnan R; Nguyen TP; De Avila G; Silva AS; Sudalagunta P; Canevarolo RR; Siqueira Silva MDC; Alugubelli RR; Dai HA; Kulkarni A; Dalton WS; Hampton OA; Welsh EA; Teer JK; Tungesvik A; Wright KL; Pinilla-Ibarz J; Sotomayor EM; Shain KH; Brayer J
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34793338
[TBL] [Abstract] [Full Text] [Related]
4. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
Wu CE; Chang CF; Huang CY; Yang CT; Kuo CS; Hsu PC; Chang JW
BMC Cancer; 2021 Jul; 21(1):859. PubMed ID: 34315431
[TBL] [Abstract] [Full Text] [Related]
5. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract] [Full Text] [Related]
6. Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
Kriston C; Hernádfői M; Plander M; Márk Á; Takács F; Czeti Á; Szalóki G; Szabó O; Matolcsy A; Barna G
Hematol Oncol; 2021 Oct; 39(4):513-520. PubMed ID: 34013974
[TBL] [Abstract] [Full Text] [Related]
7. The IKZF1-irf4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract] [Full Text] [Related]
8. Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-irf4-MYC Axis.
Murugesan A; Lassalle-Claux G; Hogan L; Vaillancourt E; Selka A; Luiker K; Kim MJ; Touaibia M; Reiman T
J Nat Prod; 2020 Dec; 83(12):3526-3535. PubMed ID: 33210536
[TBL] [Abstract] [Full Text] [Related]
9. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Walker ZJ; Idler BM; Davis LN; Stevens BM; VanWyngarden MJ; Ohlstrom D; Bearrows SC; Hammes A; Smith CA; Jordan CT; Mark TM; Forsberg PA; Sherbenou DW
Clin Cancer Res; 2021 Feb; 27(3):819-830. PubMed ID: 33109736
[TBL] [Abstract] [Full Text] [Related]
10. Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial.
Leung YY; Haaland B; Huebner JL; Wong SBS; Tjai M; Wang C; Chowbay B; Thumboo J; Chakraborty B; Tan MH; Kraus VB
Osteoarthritis Cartilage; 2018 May; 26(5):631-640. PubMed ID: 29426008
[TBL] [Abstract] [Full Text] [Related]
11. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
[TBL] [Abstract] [Full Text] [Related]
12. Wnt/β-Catenin Signaling Activates Expression of the bone-Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types.
Vega OA; Lucero CMJ; Araya HF; Jerez S; Tapia JC; Antonelli M; Salazar-Onfray F; Las Heras F; Thaler R; Riester SM; Stein GS; van Wijnen AJ; Galindo MA
J Cell Biochem; 2017 Nov; 118(11):3662-3674. PubMed ID: 28370561
[TBL] [Abstract] [Full Text] [Related]
13. Cereblon and irf4 Variants Affect Risk and Response to treatment in Multiple Myeloma.
Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
[TBL] [Abstract] [Full Text] [Related]
14. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract] [Full Text] [Related]
15. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract] [Full Text] [Related]
16. Differential effects of lenalidomide during plasma cell differentiation.
Jourdan M; Cren M; Schafer P; Robert N; Duperray C; Vincent L; Ceballos P; Cartron G; Rossi JF; Moreaux J; Chopra R; Klein B
Oncotarget; 2016 May; 7(19):28096-111. PubMed ID: 27057635
[TBL] [Abstract] [Full Text] [Related]
17. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract] [Full Text] [Related]
18. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Li S; Pal R; Monaghan SA; Schafer P; Ouyang H; Mapara M; Galson DL; Lentzsch S
Blood; 2011 May; 117(19):5157-65. PubMed ID: 21389327
[TBL] [Abstract] [Full Text] [Related]
19. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
McMillin DW; Delmore J; Weisberg E; Negri JM; Geer DC; Klippel S; Mitsiades N; Schlossman RL; Munshi NC; Kung AL; Griffin JD; Richardson PG; Anderson KC; Mitsiades CS
Nat Med; 2010 Apr; 16(4):483-9. PubMed ID: 20228816
[TBL] [Abstract] [Full Text] [Related]
20. 2-Methoxyestradiol induce the conversion of human peripheral blood memory B lymphocytes into plasma cells.
Cayer MP; Drouin M; Proulx M; Jung D
J Immunol Methods; 2010 Apr; 355(1-2):29-39. PubMed ID: 20202470
[TBL] [Abstract] [Full Text] [Related]
[Next]
